Department of Neural Sciences, Lewis Katz School of Medicine, Shriners Hospitals Pediatrics Research Center, Temple University, Philadelphia, PA 19140, USA.
Biomedical Sciences Graduate Program, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Hum Mol Genet. 2022 Jun 22;31(12):1979-1996. doi: 10.1093/hmg/ddab374.
The multi-systemic genetic disorder tuberous sclerosis complex (TSC) impacts multiple neurodevelopmental processes including neuronal morphogenesis, neuronal migration, myelination and gliogenesis. These alterations contribute to the development of cerebral cortex abnormalities and malformations. Although TSC is caused by mTORC1 hyperactivation, cognitive and behavioral impairments are not improved through mTORC1 targeting, making the study of the downstream effectors of this complex important for understanding the mechanisms underlying TSC. As mTORC1 has been shown to promote the activity of the transcriptional co-activator Yap, we hypothesized that altered Yap/Taz signaling contributes to the pathogenesis of TSC. We first observed that the levels of Yap/Taz are increased in human cortical tuber samples and in embryonic cortices of Tsc2 conditional knockout (cKO) mice. Next, to determine how abnormal upregulation of Yap/Taz impacts the neuropathology of TSC, we deleted Yap/Taz in Tsc2 cKO mice. Importantly, Yap/Taz/Tsc2 triple conditional knockout (tcKO) animals show reduced cortical thickness and cortical neuron cell size, despite the persistence of high mTORC1 activity, suggesting that Yap/Taz play a downstream role in cytomegaly. Furthermore, Yap/Taz/Tsc2 tcKO significantly restored cortical and hippocampal lamination defects and reduced hippocampal heterotopia formation. Finally, the loss of Yap/Taz increased the distribution of myelin basic protein in Tsc2 cKO animals, consistent with an improvement in myelination. Overall, our results indicate that targeting Yap/Taz lessens the severity of neuropathology in a TSC animal model. This study is the first to implicate Yap/Taz as contributors to cortical pathogenesis in TSC and therefore as potential novel targets in the treatment of this disorder.
多系统遗传性疾病结节性硬化症复合征(TSC)影响多种神经发育过程,包括神经元形态发生、神经元迁移、髓鞘形成和神经胶质发生。这些改变导致大脑皮层异常和畸形的发展。尽管 TSC 是由 mTORC1 过度激活引起的,但通过靶向 mTORC1 并不能改善认知和行为障碍,因此研究该复合物的下游效应物对于理解 TSC 的发病机制非常重要。由于 mTORC1 已被证明可促进转录共激活因子 yap 的活性,我们假设 Yap/Taz 信号的改变有助于 TSC 的发病机制。我们首先观察到 Yap/Taz 的水平在人类皮质结节样本和 Tsc2 条件性敲除(cKO)小鼠的胚胎皮质中增加。接下来,为了确定 Yap/Taz 的异常上调如何影响 TSC 的神经病理学,我们在 Tsc2 cKO 小鼠中敲除了 Yap/Taz。重要的是,尽管 mTORC1 活性持续升高, Yap/Taz/Tsc2 三重条件性敲除(tcKO)动物的皮质厚度和皮质神经元细胞大小减小,表明 Yap/Taz 在巨脑症中发挥下游作用。此外, Yap/Taz/Tsc2 tcKO 显著恢复了皮质和海马分层缺陷,并减少了海马异位形成。最后,Yap/Taz 的缺失增加了 Tsc2 cKO 动物髓鞘碱性蛋白的分布,与髓鞘形成的改善一致。总的来说,我们的结果表明,针对 Yap/Taz 可减轻 TSC 动物模型中神经病理学的严重程度。这项研究首次表明 Yap/Taz 是 TSC 皮质发病机制的贡献者,因此是治疗这种疾病的潜在新靶点。